POPULARITY
Categories
63 episodes with inhibitors
53 episodes with inhibitors
53 episodes with inhibitors
32 episodes with inhibitors
45 episodes with inhibitors
45 episodes with inhibitors
63 episodes with inhibitors
28 episodes with inhibitors
22 episodes with inhibitors
22 episodes with inhibitors
26 episodes with inhibitors
23 episodes with inhibitors
11 episodes with inhibitors
26 episodes with inhibitors
19 episodes with inhibitors
26 episodes with inhibitors
14 episodes with inhibitors
20 episodes with inhibitors
25 episodes with inhibitors
30 episodes with inhibitors
18 episodes with inhibitors
10 episodes with inhibitors
10 episodes with inhibitors
13 episodes with inhibitors
29 episodes with inhibitors
19 episodes with inhibitors
22 episodes with inhibitors
17 episodes with inhibitors
8 episodes with inhibitors
10 episodes with inhibitors
9 episodes with inhibitors
12 episodes with inhibitors
12 episodes with inhibitors
18 episodes with inhibitors
8 episodes with inhibitors
8 episodes with inhibitors
6 episodes with inhibitors
13 episodes with inhibitors
25 episodes with inhibitors
7 episodes with inhibitors
17 episodes with inhibitors
3 episodes with inhibitors
10 episodes with inhibitors
6 episodes with inhibitors
6 episodes with inhibitors
4 episodes with inhibitors
4 episodes with inhibitors
7 episodes with inhibitors
7 episodes with inhibitors
6 episodes with inhibitors
6 episodes with inhibitors
9 episodes with inhibitors
3 episodes with inhibitors
6 episodes with inhibitors
Trends and Innovations from Barcelona (6.20.2025) AI Advances axSpA Diagnosis with Multimodal MRI IL-17 Inhibitors in Psoriatic Arthritis IL-17 Inhibitors for Axial Spondyloarthritis New IL-17 Inhibition New Molecular Constructs
In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/The-DOT1L-inhibitor-pinometostat-reduces-H3K79AUGMENT 101: https://ascopubs.org/doi/10.1200/JCO.24.00826Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study: https://ashpublications.org/blood/article/doi/10.1182/blood.2025028357/537139/Menin-inhibition-with-revumenib-for-NPM1-mutatedKOMET-001: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00386-3/abstractSAVE trial: https://ashpublications.org/blood/article/144/Supplement%201/216/530724/Phase-I-II-Study-of-the-All-Oral-Combination-ofKOMET-007: https://library.ehaweb.org/eha/2025/eha2025-congress/4159213/harry.erba.ziftomenib.combined.with.intensive.induction.chemotherapy.2872B329.in.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31560%2Amarker%3D5843%2Afeatured%3D19595MEN1 mutations: https://www.nature.com/articles/s41586-023-05755-9
In today's episode, we had the pleasure of speaking with Alexey Danilov, MD, PhD, about current challenges and emerging treatment approaches for the management of leukemia and lymphoma that were published in a manuscript based on proceedings from the inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. In our exclusive interview, Dr Danilov highlighted recent advances and controversies in the treatment of select patients with hematologic malignancies. He noted chemotherapy-free regimens that are shifting treatment paradigms in mantle cell lymphoma, preferred and emerging BTK inhibitors for the management of chronic lymphocytic leukemia, and the evolution of CD19-directed CAR T-cell therapies for diffuse large B-cell lymphoma. Dr Danilov concluded by taking a forward glance at future developments like BTK degraders and novel CAR T-cell therapy targets.
Featuring perspectives from Dr Virginia F Borges, Ms Jamie Carroll, Mr Ronald Stein and Dr Seth Wander, including the following topics: Introduction (0:00) Role of CDK4/6 Inhibitors in Localized and Metastatic Hormone Receptor (HR)-Positive Breast Cancer (12:49) PI3K Inhibition as First-Line Treatment for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (38:24) Clinical Utility of AKT and PI3K Inhibitors in Progressive HR-Positive mBC (1:01:44) Current and Future Role of Oral Selective Estrogen Receptor Degraders in HR-Positive mBC (1:24:38) NCPD information and select publications
Episode 367: Pharmacology 101: PARP Inhibitors “We know that in cells that are proliferating very quickly, including cancer cells, single-strand DNA breaks are very common. When that happens, these breaks are often repaired by the PARP enzyme, and the cells can continue their replication process. If we block PARP, that repair cannot happen. So in blocking that, these single-strand breaks then lead to double-strand breaks, which ultimately is leading to cell apoptosis,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the PARP inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 13, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the use of PARP inhibitors in cancer care. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 232: Managing Fatigue During PARP Inhibitor Maintenance Therapy Episode 227: Biomarker Testing, PARP Inhibitors, and Oral Adherence During Ovarian Cancer Maintenance Therapy ONS Voice articles: PARP Inhibitors and Ovarian Cancer Genomics May Trick PARP Inhibitors to Treat More Cancers Oncology Drug Reference Sheet: Niraparib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing articles: PARP Inhibition: Genomics-Informed Care for Patients With Malignancies Driven by BRCA1/BRCA2 Pathogenic Variants Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers Oncology Nursing Forum article: Familiarity and Perceptions of Ovarian Cancer Biomarker Testing and Targeted Therapy: A Survey of Oncology Nurses in the United States Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Biomarker Database ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The big toxicities here to watch for are primarily hematologic toxicities. It is one of those targeted therapies that does affect blood cell counts. So I'd say the blood cell count that is most commonly affected here is the hemoglobin. So, anemia very frequent complication that we see, probably a little bit more with olaparib compared with other drugs, but we see it as a class side effect. And we can also see neutropenia and thrombocytopenia with these agents, probably a little bit more with niraparib versus the others, but again, you can see it across all of these drugs.” TS 8:16 “We mentioned that rare risk of MDS and AML. This isn't a particularly scary thing if you talk to patients about it. Because of the rarity that we see this, it isn't something that we need to overemphasize, but I think careful monitoring of blood counts in is stressing the importance of that and early intervention here is very important.” TS 16:55 “This is a collaborative effort. And because of the home administration here, these patients do need to be followed very closely. So we are not laying eyes on them usually with the frequency that we do when we have patients actually coming into our infusion centers for treatments—so making sure that there is a plan for regular follow-up with these patients to ensure that they're getting that lab work done, that that's being looked at closely, that we're adjusting the dose if we need to based on that lab work, that we are managing the patient's fatigue. Again, that potentially dose reductions may be needed if patients are having that extreme fatigue.” TS 19:34 “I think one of those [misconceptions] could be that they're only effective in patients that have that BRCA1/2 mutation. And again, remember here that there is some data in particular disease states that we can use them and that they work in the absence of those mutations.” TS 25:12
Can we do more than prescribe pills to address men's sexual health complaints? In this episode of the BackTable Urology Podcast, men's health expert Dr. Mohit Khera from Baylor College of Medicine joins guest host Dr. Amy Pearlman for a deep dive into testosterone management and the full spectrum of erectile dysfunction therapies. --- SYNPOSIS The conversation covers daily tadalafil use, lifestyle optimization, and the nuanced role of off-label medications. Dr. Khera also highlights emerging technologies like the Tech Ring and radiofrequency treatments, alongside practical insights into semen analysis and hormonal health markers. Throughout, he emphasizes a holistic, patient-centered approach to sexual health—blending medical therapy with meaningful lifestyle change. This is a must-listen for general urologists, men's health specialists, and trainees looking to expand their toolkit in this evolving field. --- TIMESTAMPS 00:00 - Introduction02:13 - Erectile Dysfunction and Testosterone08:05 - Young Men's Health and Early Detection10:20 - Semen Analysis for Overall Health12:50 - Daily Tadalafil and Its Benefits16:40 - Proactive Sexual Health Management21:28 - Female Sexual Health25:16 - Treating Delayed Ejaculation28:53 - Psychogenic Erectile Dysfunction31:16 - Technology in Sexual Health35:54 - Lifestyle Modifications for Better Sexual Health41:55 - Resources and Referrals for Patients44:30 - Final Thoughts
EIQnutrition.com
Dr. Grant Tinsley joins the discussion as the body composition expert.Myostatin is a key regulator of muscle growth.Wendy Whippete the most jacked muscled up dogThe concern of GLP-1 receptor agonists and muscle mass loss.Overview of Courage trial looking at semaglutide and trevogrumab and lean mass lossUpcoming Believe trial coming out (bimagrumab and semaglutide)Exercise remains crucial for muscle health and function.MRI data from SURPASS MRI provides new insights into muscle volume changes.The combination of medications may have varying effects on muscle mass.Caution is advised regarding the long-term effects of new drugs.Clinical benefits of medications often outweigh concerns about muscle loss.Future research will explore the synergy between exercise and medication.Other docs who lift podcasts with Dr. Grant:Tirzepatide muscle lossLean mass loss and GLP-1 meds
Featuring perspectives from Dr Daniel George, Dr Leonard G Gomella and Dr Evan Y Yu, moderated by Dr George, including the following topics: Introduction (0:00) Current Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Gomella (3:42) Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr Yu (35:37) Emerging Role of AKT Inhibition for mHSPC — Dr George (1:06:18) CME information and select publications
SGLT2 Inhibitors Cardiovascular and Safety Outcomes in Chronic Diseases by Citeline
Dr Leonard G Gomella from the Sidney Kimmel Cancer Center in Philadelphia, Pennsylvania, Dr Evan Y Yu from the Fred Hutchinson Cancer Center in Seattle, Washington, and Dr Daniel George from Duke Cancer Institute in Durham, North Carolina, discuss important clinical datasets and patient cases relevant to AKT inhibition in the care of patients with prostate cancer. CME information and select publications here.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have revolutionized treatment for type 2 diabetes, heart failure, and chronic kidney disease—but they're creating new challenges for anesthesia professionals. With more patients on these medications heading to surgery, understanding their unique perioperative risks has never been more critical.At the heart of this issue lies euglycemic ketoacidosis—a potentially life-threatening complication that's particularly insidious because it lacks the classic hyperglycemia that would normally trigger suspicion. We dive deep into the latest evidence, revealing that patients on SGLT2 inhibitors have an increased risk of developing postoperative ketoacidosis compared to those not taking these medications, with significantly worse outcomes when complications occur.We present a practical algorithm for risk stratification, considering factors like procedure duration, anesthesia type, diabetes control, and comorbidities. You'll learn which patients should hold their medication, which can proceed with caution, and what monitoring strategies to implement when patients haven't properly discontinued their medication before surgery. This guidance is especially valuable for emergency cases where postponement isn't an option.Whether you're developing institutional protocols or making decisions for individual patients, this episode equips you with the knowledge to navigate the complexities of SGLT2 inhibitor management in the perioperative period. Subscribe to stay informed about the latest in anesthesia patient safety and join our mission to ensure no one is harmed by anesthesia care.For show notes & transcript, visit our episode page at apsf.org: https://www.apsf.org/podcast/257-sweet-trouble-perioperative-management-of-sglt2-inhibitors/© 2025, The Anesthesia Patient Safety Foundation
In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:Key Comorbidities in Patients with HR+/HER2- MBCImpact of PolypharmacyRole of APPs in Comprehensive CareRole of CDK4/6 Inhibitors and Other Treatments for HR+/HER2- MBCUtility of RWE dataCommunicating Treatment Options With Patients and CaregiversUnderstanding Patient Goals and Coordinating With the Multidisciplinary Team to Individualize Treatment and Maximize Quality of LifeLink to full program:https://bit.ly/4jCQe38
Marla C. Dubinsky, MD / David T. Rubin, MD - TNF Inhibitors in Inflammatory Bowel Disease: How Can We Realize Opportunities to Optimize Clinical and Patient Outcomes?
Drs Carol H. Wysham and Liana K. Billings discuss how to incorporate SGLT2 inhibitors and GLP-1 receptor agonists into the management of patients with type 2 diabetes and chronic kidney disease. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002049. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Chronic Kidney Disease (CKD) https://emedicine.medscape.com/article/238798-overview Global, Regional, and National Burden of Chronic Kidney Disease Due to Diabetes Mellitus Type 2 From 1990 to 2021, With Projections to 2036: A Systematic Analysis for the Global Burden of Disease Study 2021 https://pubmed.ncbi.nlm.nih.gov/40034386/ Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR https://pubmed.ncbi.nlm.nih.gov/36514729/ New Creatinine- and Cystatin C-Based Equations to Estimate GFR Without Race https://pubmed.ncbi.nlm.nih.gov/34554658/ Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/38785209/ Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://pubmed.ncbi.nlm.nih.gov/30990260/ Dapagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/32970396/ Empagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/36331190/ Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 https://pubmed.ncbi.nlm.nih.gov/39651975/ CKD Early Identification & Intervention Toolkit https://kdigo.org/wp-content/uploads/2019/01/ISN_KDIGO_EarlyScreeningBooklet_WEB_updatedOct11.pdf Combination Therapy as a New Standard of Care in Diabetic and Non-Diabetic Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/39907542/ Living With Chronic Kidney Disease and Type 2 Diabetes Mellitus: The Patient and Clinician Perspective https://pubmed.ncbi.nlm.nih.gov/36282450/
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, a thoracic medical oncologist from the Sylvester Cancer Center. Together, they dived into the latest updates on anti-EGFR drugs used in non-small cell lung cancer (NSCLC) with EGFR mutations. In this informative discussion, they covered: • The evolution of EGFR inhibitors, including Afatinib, Osimertinib, Amivantamab, and Lazertinib. • Common side effects associated with these treatments, such as diarrhea, skin toxicity, and infusion-related reactions. • Strategies for managing these side effects to improve patient quality of life and treatment adherence. • Insights from recent studies, including the SKIPirr trial and the MARIPOSA study, highlighting the benefits of new combinations and treatment approaches. Youtube: https://youtu.be/v6fb6nx0YY4 Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Join us as we explore how proactive management of side effects can maximize the effectiveness of these therapies and enhance patient outcomes. Don't forget to check out our other ToxCheck discussions, treatment algorithms, and conference highlights!
Over the past few years, the MS research community has been following developments in a new class of therapies called Bruton's tyrosine kinase inhibitors (BTKis). At ECTRIMS 2024, the results of two tolebrutinib trials were presented as late-breaking abstracts by Dr. Robert Fox, Neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic in the US, and Dr. Jiwon Oh, Neurologist at St. Michael's Hospital at the University of Toronto. The full results were recently published in The New England Journal of Medicine. In this episode, host Brett Drummond of MStranslate spoke with Drs. Oh and Fox about the outcomes and what they mean for people with MS.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EMS865. CME/AAPA/IPCE credit will be available until May 5, 2026.Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies & Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Neurological Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EMS865. CME/AAPA/IPCE credit will be available until May 5, 2026.Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies & Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Neurological Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EMS865. CME/AAPA/IPCE credit will be available until May 5, 2026.Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies & Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Neurological Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EMS865. CME/AAPA/IPCE credit will be available until May 5, 2026.Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies & Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Neurological Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EMS865. CME/AAPA/IPCE credit will be available until May 5, 2026.Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies & Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Neurological Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EMS865. CME/AAPA/IPCE credit will be available until May 5, 2026.Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies & Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Neurological Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
In this three-part series, Jonathan Sackier sits down with Richard Conway, rheumatologist, researcher, and educator. Together, they delve into cutting-edge insights on polymyalgia rheumatica, immune ageing, and the future of rheumatology care. 01:47 – Interstitial Lung Disease 08:25 – Evolution of Rheumatology 11:39 – Wishes for Healthcare
BUFFALO, NY — May 14, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 4, on April 10, 2025, titled “Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation.” In this study, first author Masahiko Takahashi and corresponding author Keisuke Okawa led a research team from Kagawa Prefectural Central Hospital and Hyogo Medical University that investigated whether Factor Xa inhibitors (Xa-Is)—a type of blood thinner—can reduce the risk of heart-related complications in patients over 80 with nonvalvular atrial fibrillation (NVAF). The study found that patients using Xa-Is experienced significantly fewer cardiovascular problems than those on other anticoagulants. This finding is especially relevant, as older adults face a high risk of both stroke and heart disease. Atrial fibrillation is a common heart rhythm disorder, particularly in the elderly, that increases the risk of blood clots, heart failure, and stroke. Anticoagulants are often prescribed to prevent clots, but not all types have the same effects on heart health. This study focused on comparing Xa-Is—specifically rivaroxaban, apixaban, and edoxaban—with commonly used drugs such as warfarin and dabigatran. Researchers followed more than 1,000 patients aged 80 and above for up to five years to assess the long-term impact of these medications on cardiovascular outcomes. Patients who used Xa-Is had significantly lower rates of heart failure, artery disease, and cardiovascular death. The risk of cardiovascular problems in the Xa-I group was less than half that of those on non-Xa-I medications. These benefits remained even after adjusting for factors like age, existing heart conditions, and kidney function. Additionally, stroke and all-cause death rates were notably lower in the Xa-I group. “Xa-Is may be useful for not only anticoagulation but also the prevention of cardiovascular events in very old patients with NVAF.” What makes Xa-Is different, according to the researchers, is their ability to inhibit a specific biological pathway—known as Factor Xa–PAR2—that contributes to inflammation, fibrosis, and damage in blood vessels and heart tissue. This effect extends beyond their traditional role in preventing blood clots. Although the study was conducted at a single medical center in Japan, its rigorous design and long follow-up period enhance the reliability of the findings for real-world clinical decision-making. While further studies, especially across multiple centers, are needed to confirm the full range of benefits, this study strongly suggests that Xa-Is may offer broader cardiovascular protection for very old patients. The findings could influence how clinicians choose blood thinners for elderly individuals with atrial fibrillation, potentially improving both survival and quality of life in this growing population. DOI - https://doi.org/10.18632/aging.206238 Corresponding author - Keisuke Okawa - k-ookawa@chp-kagawa.jp Video short - https://www.youtube.com/watch?v=YtbYpfVDVDI Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206238 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, Factor Xa inhibitor, atrial fibrillation, older patient, cardiovascular events To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
In today's episode, supported by SpringWorks Therapeutics, we spoke with Christopher L. Moertel, MD, about the evolution of treatments for neurofibromatosis type 1 (NF1)–associated plexiform neurofibromas (PN). Dr Moertel is a professor and the Pediatric Neuro-Oncology Fellowship Program director in the Division of Pediatric Hematology/Oncology, a faculty member in the Department of Pediatrics, medical director of the Pediatric Neuro-Oncology and Neurofibromatosis Programs, co-medical director of the Katie Hageboeck Children's Cancer Research Fund Clinic, clinical neuro-oncology leader of the Brain Tumor Program, and the Kenneth and Betty Jayne Dahlberg Professor at the University of Minnesota School of Medicine in Minneapolis. In our exclusive interview, Dr Moertel discussed the expansion of the NF1-associated PN treatment paradigm to include the MEK inhibitors mirdametinib (Gomekli) and selumetinib (Koselugo); the benefits of offering treatment options in oral formulations; the toxicities associated with MEK inhibitors; the importance of managing these adverse effects to ensure long-term treatment adherence; and the need for continued oncology education to optimize treatment outcomes for this population.
“The signaling and that binding of the MET and the HGF help, in a downstream way, lead to cell proliferation, cell motility, survival, angiogenesis, and also invasion—so all of those key cancer hallmarks. And because of it being on an epithelial cell, it's a really good marker because it's found in many, many different types of cancers, so it makes it what we call kind of a nice actionable mutation,” ONS member Marianne Davies, DNP, ACNP, AOCNP®, FAAN, senior oncology nurse practitioner at Yale Comprehensive Cancer Center in New Haven, CT, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the MET inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 9, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to MET inhibitors. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Capmatinib Oncology Drug Reference Sheet: Tepotinib Predictive and Diagnostic Biomarkers: Identifying Variants Helps Providers Tailor Cancer Surveillance Plans and Treatment Selection ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) Telephone Triage for Oncology Nurses (third edition) ONS courses: Safe Handling Basics ONS Biomarker Database ONS Huddle Cards: Monoclonal Antibodies Targeted Therapy ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets IV Chemotherapy Education Sheets Drugs@FDA To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The MET receptor was actually identified back in 1984. And it was actually identified as an oncogene in osteosarcoma. And so basically what that MET receptor does—it's a tyrosine kinase pathway, and the ligand that it attaches to is something called HGF/SF. That's hepatocyte growth factor/scatter factor. And so this MET pathway tyrosine kinase pathway is really important in tumor cell growth and migration. And it's expressed specifically on epithelial cells, so that's going to really help us in identifying how it can be a pathway for cancer treatments.” TS 1:35 “But in the particular classes, there kind of are some unique things that are with these MET inhibitors. For example, crizotinib, we found early on, causes some vision changes. Patients would report things like floaters or a little bit of blurry vision. For the capmatinib, things like elevation of amylase and lipase, fluid retention and bloating, and hypersensitivity reactions and photosensitivity.” TS 7:36 “Other things to teach for the TKI is the self-management strategies in terms of nausea management and dietary changes for the risk of peripheral edema. Having them do things like maybe doing daily weights, or at least weights every other day, and sometimes doing limb measurements so it can help us really quantify the amount of fluid retention they have. And then from a nursing perspective, meeting with these patients, is to do really good skin inspection. When people have peripheral edema, they're at risk for skin breakdown, and that can lead obviously to infection.” TS 16:06 “The biggest [misconception] is that people assume that all MET mutations are going to be equally responsive to the same targeted therapies, that all of the abnormalities are the same and react the same, and they really don't. We're really diving down and carving that pie thinner and thinner in terms of each individual MET abnormality, in terms of what drugs responds it to and what that means for patient outcomes and prognosis.” TS 25:21
Bradley P. Dixon, MD, FASN / Carla M. Nester, MD, MSA, FASN - Getting to the Root of the Problem: Unlocking the Potential of Novel Complement Inhibitors in C3G and IC-MPGN
Drs. VanderPluym and Starling review the updated position statement from the American Headache Society indicating that CGRP-targeting migraine therapies should be considered as a first-line option.
Featuring perspectives from Prof Rebecca A Dent and Dr Nancy U Lin, including the following topics: Introduction: A New Paradigm for Triple-Positive Breast Cancer? (0:00) CDK4/6 Inhibitors for HR-Positive, HER2-Negative Breast Cancer (10:06) Oral Selective Estrogen Receptor Degraders for HR-Positive, HER2-Negative Breast Cancer (21:17) Treatment of PIK3CA/PTEN/AKT-Mutated Breast Cancer (31:34) Antibody-Drug Conjugates (ADCs) for HR-Positive, HER2-Negative Breast Cancer (38:41) ADCs for HER2-Positive Breast Cancer (46:30) HER2-Targeting Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer (53:26) ADCs for Advanced Triple-Negative Breast Cancer (58:29) CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 1: Current Role of Covalent Bruton Tyrosine Kinase Inhibitors and Bcl-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL) — Paolo Ghia, MD, PhD CME information and select publications
Corrosion control is fundamental to the success of any water treatment program, but how often do we question the limitations of the tools we rely on? In this episode of Scaling UP! H2O, host Trace Blackmore welcomes back returning guest Mike Standish, Vice President of Water Additives at MFG Chemical, to explore the evolving role of maleic acid-based corrosion inhibitors in industrial water treatment. Drawing on decades of expertise, Mike shares practical insights into when — and when not — to use these innovative solutions to meet today's complex challenges. Understanding the Corrosion Control Toolbox Mike Standish opens the conversation by reframing corrosion control strategies through the lens of a toolbox analogy. With limited primary approaches — from phosphate-based to organic and metal-based chemistries — the success of corrosion management depends on matching the right tool to the right application. Mike stresses the importance of avoiding overcomplication and focusing on the fundamental chemical pathways for mild steel protection. Organic vs. Inorganic Approaches The discussion turns to the critical differences between organic and inorganic inhibitors. While inorganic phosphates remain cost-effective mainstays, organic phosphonates, including maleic acid-derived materials, offer advantages in high pH, high hardness, and oxidizing environments. Mike emphasizes that “organic” in water treatment bears no relation to natural or sustainable products, a frequent misconception among newcomers to the industry. Why Maleic Acid-Based Inhibitors Matter Maleic acid phosphonates distinguish themselves with exceptional oxidant stability, a feature increasingly necessary as continuous halogenation becomes standard practice. Mike explains the chemistry behind maleic acid derivatives and how the ability to tailor molecular structures creates flexibility for specific field conditions — such as scaling tendencies, pH control, and calcium carbonate formation risks. Best Practices for Application and Measurement Field success with maleic acid-based inhibitors hinges on proper dosage and testing. Mike shares lessons from real-world trials, emphasizing that underfeeding is a common mistake that compromises corrosion rates. Accurate differentiation between orthophosphate and phosphonate concentrations is vital for precise monitoring, and bench testing must closely simulate real-world surface-to-volume ratios to yield reliable predictions. The Future of Corrosion Control In a forward-looking discussion, Mike predicts that industry consolidation will trigger a second wave of entrepreneurial water treatment companies. His vision underscores the ongoing need for technical excellence, adaptability, and innovation in corrosion management practices as the industry evolves. This episode challenges water treatment professionals to rethink their corrosion strategies with a sharper, more informed approach. Maleic acid-based inhibitors are not a universal solution, but when applied thoughtfully, they offer powerful advantages for specific operational demands. Explore more episodes, challenge your assumptions, and lead the way in advancing our industry's standards of technical excellence. Don't forget to subscribe to Scaling UP! H2O for more expert insights in water treatment. Stay engaged, keep learning, and continue scaling up your knowledge! Timestamps 02:50 – Trace Blackmore shares a recap from previous episode. He also shares about the AWT Innovation Award 06:40 - Water You Know with James McDonald 08:00 - Upcoming Events for Water Treatment Professionals 12:38 - Welcoming back guest Mike Standish, Vice President of Water Additives – MFG Chemical 15:10 – The Value of True Industry Knowledge vs. Surface Information 23:10 – Starting the Technical Discussion: The Corrosion Control Toolbox Analogy 26:07 – Explanation of anodic vs. Cathodic protection mechanisms 37:35 – Situational Applications: When to use maleic acid-based inhibitors 40:11 – Lessons learned from field trials on dosage and corrosion control 41:28 – Importance of Accurate modeling and Surface-to-volume ratios Quotes “You going to get more than you can give” – Mike Standish “Picking the right tool for the right job” – Mike Standish "Stepping away from work for a mission trip doesn't just help others—it helps you gain a new perspective." – Mike Standish “You can't just throw a new additive into a system and hope for the best. You need data, understanding of limits, and clear expectations.” “There's going to be a second generation of AWT companies as industry consolidation continues.” Connect with Mike Standish Phone: (615) 207- 3018 Email: mike.standish@radicalpolymers.com Website: https://www.radicalpolymers.com/ LinkedIn: https://www.linkedin.com/in/mike-standish-7890627/ Click HERE to Download Episode's Discussion Guide Guest Resources Mentioned Mild Steel Corrosion Control using a Maleic-Based Inhibitor Purposely Built – Introduction of a New Copolymer for Multifunctional Applications Technical Paper Scaling UP! H2O Resources Mentioned AWT (Association of Water Technologies) Scaling UP! H2O Academy video courses Submit a Show Idea The Rising Tide Mastermind Legionella Awareness Resources 417 How To Live a Life of Significance: Insights from Aaron Walker 014 The One with Mike Standish 223 Pinks and Blues: Phosphonate Replacements 350 Polymer Perspectives: Understanding Copolymer Innovations in Water Treatment 176 The One About Tagged Polymer Technologies Water You Know with James Question: What do you call the large-diameter tube in firetube boilers where the combustion of fuel takes place? 2025 Events for Water Professionals Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.
In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss how to address questions related to BTK Inhibitors with patients. Show reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2415985 https://www.nejm.org/doi/full/10.1056/NEJMoa2415988
"It's an exciting time. We're not just managing chronic disease. We're reimaging its trajectory" per dermatologist Dr. Mona Shahriari, Central Connecticut Dermatology and NPF Medical Board member as she discusses the latest from the AAD Annual Meeting like head-to-head studies between IL-17 and IL-23 inhibitors, early intervention for psoriasis, use of GLP-1's, new TYK2 and oral IL-23, and high impact sites with moderator Archie Franklin.
In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss the clinical trial data available in both the relapsing and progressive cohorts. Show reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2415985 https://www.nejm.org/doi/full/10.1056/NEJMoa2415988
In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss how Bruton Tyrosine Kinase (BTK) Inhibitors work and how they vary from other disease-modifying therapies. Show reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2415985 https://www.nejm.org/doi/full/10.1056/NEJMoa2415988
What do you do when most trials suggest benefit for an intervention, but then a new trial suggests harm? We thought steroids in pneumonia was a settled question, but REMAP-CAP had other plans!We also review a new RCT for BP targets in patients with hypertension and diabetes, a new aldosterone synthase inhibitor for hypertension, and reduced dose apixaban for cancer-associated thrombosis. Hydrocortisone for Severe CAP (REMAP-CAP)Predicting Benefit of Corticosteroids in PneumoniaIntensive BP Control in Patients with Diabetes (BPROAD)Lorundrostat for Uncontrolled Hypertension (ADVANCE-HTN)Reduced Dose Apixaban for Cancer Associated Thrombosis (API-CAT)Music from Uppbeat (free for Creators!): https://uppbeat.io/t/soundroll/dope License code: NP8HLP5WKGKXFW2R
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.
Dr. Justin Abbatemarco talks with Dr. Jiwon Oh about Bruton Tyrosine Kinase (BTK) Inhibitors and the recent data on tolebrutinib in multiple sclerosis. Read the related article on Tolebrutinib versus Teriflunomide in The New England Journal of Medicine. Read the related article on Tolebrutinib in Nonrelapsing Secondary Progressive MS in The New England Journal of Medicine. Disclosures can be found at Neurology.org.
Featuring perspectives from Dr Aditya Bardia, Dr Virginia F Borges, Dr Harold J Burstein and Dr Joyce O'Shaughnessy, including the following topics: Introduction (0:00) HER2-Positive Breast Cancer — Dr O'Shaughnessy (3:13) Triple-Negative Breast Cancer — Dr Bardia (32:56) Personalizing Adjuvant Therapy for Patients with HR-Positive Breast Cancer — Dr Borges (57:35) Current Role of CDK4/6 Inhibitors in the Localized Setting — Dr Burstein (1:25:15) CME information and select publications
Featuring perspectives from Dr Aditya Bardia, Dr Virginia F Borges, Dr Harold J Burstein and Dr Joyce O'Shaughnessy, including the following topics: Introduction (0:00) CDK4/6 Inhibitors for HR-Positive Metastatic Breast Cancer (mBC) — Dr Borges (9:56) Targeting the PTEN/PI3K/AKT Pathway in HR-Positive mBC — Dr Burstein (35:20) Role of Oral Selective Estrogen Receptor Degraders in the Management of HR-Positive mBC — Dr O'Shaughnessy (1:03:07) Antibody-Drug Conjugates for HR-Positive mBC — Dr Bardia (1:36:12) CME information and select publications
Featuring perspectives from Dr Nicole Lamanna and Dr Kerry Rogers, including the following topics: Introduction (0:00) Current Role of Covalent Bruton Tyrosine Kinase and Bcl-2 Inhibitors in Managing Chronic Lymphocytic Leukemia — Dr Lamanna (10:55) Novel Agents and Combination Strategies — Dr Rogers (31:21) CME information and select publications
“It's been known for quite a while that [KRAS] is a mutation that leads to cancer development, but for really over four decades, researchers couldn't figure out a way to target it. And so, it was often considered something that was undruggable. But all of this changed recently. So about four years ago, in 2021, we had the approval of the first KRAS inhibitor. So it's specifically a KRAS G12C inhibitor known as sotorasib,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the KRAS inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 11, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to KRAS inhibitors used for cancer treatment. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Cancer Symptom Management Basics series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: First KRAS-Targeted Therapy Receives FDA Approval for Lung Cancer Oncology Drug Reference Sheet: Adagrasib Oncology Drug Reference Sheet: Sotorasib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS course: Safe Handling Basics ONS video: What is the role of the KRAS biomarker in NSCLC? ONS Targeted Therapy Huddle Card ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets Lumakras® (sotorasib) manufacturer website Krazati® (adagrasib) manufacturer website UpToDate Lexidrug (formerly Lexicomp) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “If we look at specifically non-small cell lung cancer, this KRAS mutation is one of the most frequently detected cancer drivers or driver mutations. It's thought that about a quarter of cases of non-small cell lung cancer have this KRAS mutation, and it's usually a specific amino acid substitution that we see in non-small cell lung cancer, so what's known as KRAS G12C mutation.” TS 2:31 “Both of these agents, sotorasib and adagrasib, have the same mechanism of action. They bind to a pocket, very specifically on the KRAS G12C protein, and they lock it in an inactive state so that it can't cause that downstream uncontrolled signaling to happen. So they're kind of shutting down the signaling, and therefore you don't get that uncontrolled cell growth and proliferation.” TS 4:27 “Another big difference to point out, and one that is often used in clinical practice to differentiate when to use these agents, is specifically adagrasib is known to have activity in patients with metastatic non-small cell lung cancer that have active brain metastases. In the clinical trial, they included patients with active brain metastases, and they found that this drug has great [central nervous system] penetration. And so it may be considered the agent of choice in patients with brain metastases.” TS 7:19 “Other considerations—I think one of the big ones—is that there are a lot of drug interactions. Just specifically calling one out that I think is pretty impactful, is sotorasib has an interaction with acid-suppressing medications. So there is the recommendation to avoid [proton pump inhibitors] and H2 antagonists in patients receiving sotorasib. They can take antacids, but you would need to space those out from their dose of sotorasib.” TS 14:14 “This needs to be a collaborative endeavor to make sure these patients are monitored appropriately. We are putting a lot of responsibility on the patients with all of this. So, again, completely administered generally in the home setting, a lot of monitoring, a lot of adverse effects, need for reporting and management—so there's a lot happening here. And it takes a team to accomplish this and to do it right. And I firmly believe that this is often a collaborative effort between our pharmacy and oncology nursing teams to make this happen. Working together to ensure outreach to patients—I think that patients are often more successful with these medications with early identification of toxicities when we're doing scheduled outreach.” TS 19:44
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Story at-a-glance Suppression of mitochondrial ATP production prevents apoptosis and activates the NLRP3 inflammasome, a key player in inflammation and disease Inhibitors of oxidative phosphorylation (OXPHOS) lead to changes in mitochondrial cristae structure and retention of cytochrome c, which is necessary for NLRP3 activation but not sufficient on its own Activation of the NLRP3 inflammasome requires two signals, one of which is mitochondrial, highlighting the complexity of its regulation Diverse NLRP3 activators share the ability to suppress apoptosis, allowing damaged cells to survive and contributing to chronic inflammation and cancer Mitochondrial dysfunction is closely linked to inflammation and various diseases, emphasizing the importance of understanding these mechanisms for optimal health
Dr. Keith Baar is a Professor at the University of California, Davis in the Department of Physiology and Membrane Biology. During his Ph.D. studies, his research revealed that mechanical strain on muscle fibers activates the mammalian target of rapamycin (mTOR) signaling pathway, a crucial regulator of muscular hypertrophy. Subsequently, he studied the molecular dynamics of skeletal muscle adaptation to endurance training under the guidance of Dr. John Holloszy, a legend in the field of exercise physiology, considered the father of modern exercise biochemistry. Building on all of this experience, he conducted research into tendon health and the potential for engineering ligaments, which could have implications for treatment and recovery from injuries.Sponsors:Cresset prestigious family office for CEOs, founders, and entrepreneurs: https://cressetcapital.com/tim (book a call today)AG1 all-in-one nutritional supplement: https://DrinkAG1.com/Tim (1-year supply of Vitamin D (and 5 free AG1 travel packs) with your first subscription purchase.)Shopify global commerce platform, providing tools to start, grow, market, and manage a retail business: https://shopify.com/tim (one-dollar-per-month trial period)*Links to everything discussed: https://tim.blog/2025/02/26/dr-keith-baar/Timestamps:[00:00:00] Start [00:07:12] How I discovered Keith's work through a tweet about tennis elbow and rock climbing.[00:07:54] Emil Abrahamsson's hangboard training protocol.[00:09:20] The fundamental principles of strength training and connective tissue adaptation.[00:10:36] mTOR complex 1 and its role in muscle growth.[00:12:06] Engineered ligaments and the discovery of minimal effective doses for tendon adaptation.[00:13:50] The refractory period between optimal tendon loading sessions.[00:16:42] Rapamycin's effects on muscle hypertrophy.[00:18:49] Protocols for tennis elbow rehabilitation.[00:20:28] Why isometrics work better than eccentrics for tendon healing.[00:22:14] Stress shielding and how load distribution affects tendon healing.[00:29:07] The misconception about eccentric loading for tendon injuries and why velocity matters.[00:29:58] Ideal duration for isometric holds (10-30 seconds) based on injury status.[00:33:50] My elbow issues and current rehab approach.[00:36:02] Overcoming vs. yielding isometrics and optimal loading strategies.[00:47:11] Dr. Barr's movement prescription for my tennis elbow.[00:52:18] Loading timing post-surgery and RICE protocol criticism.[00:56:58] Achilles tendon rehabilitation after surgery.[01:00:18] Critique of orthopedic suturing techniques and recommendation for resorbable sutures.[01:04:02] Multiple position isometrics for tennis elbow rehabilitation.[01:07:26] Collagen synthesis, supplementation, and vitamin C timing.[01:12:59] Critique of BPC-157 and other injectable peptides for tendon healing.[01:18:19] Evaluation of orthobiologics' (PRP, prolotherapy, stem cells) effectiveness.[01:21:37] JAK-STAT inhibitor drugs and their effects on tendon growth.[01:25:35] Drugs that increase risk of tendon ruptures (fluoroquinolones, AT-1 receptor drugs).[01:29:33] How estrogen affects tendon stiffness and injury risk in women.[01:32:48] Testosterone's opposite effects on tendon compared to estrogen.[01:35:31] Protein intake recommendations and timing.[01:40:11] Ketogenic diet effects on mitochondrial biogenesis and longevity.[01:41:57] Comparison of ketogenic diet, low protein diet, and rapamycin for longevity.[01:47:19] Inflammation's role in adaptation and when to reduce it.[01:51:17] Timing of ice baths relative to training for optimal recovery.[01:52:33] Parting thoughts.*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissPast guests on The Tim Ferriss Show include Jerry Seinfeld, Hugh Jackman, Dr. Jane Goodall, LeBron James, Kevin Hart, Doris Kearns Goodwin, Jamie Foxx, Matthew McConaughey, Esther Perel, Elizabeth Gilbert, Terry Crews, Sia, Yuval Noah Harari, Malcolm Gladwell, Madeleine Albright, Cheryl Strayed, Jim Collins, Mary Karr, Maria Popova, Sam Harris, Michael Phelps, Bob Iger, Edward Norton, Arnold Schwarzenegger, Neil Strauss, Ken Burns, Maria Sharapova, Marc Andreessen, Neil Gaiman, Neil de Grasse Tyson, Jocko Willink, Daniel Ek, Kelly Slater, Dr. Peter Attia, Seth Godin, Howard Marks, Dr. Brené Brown, Eric Schmidt, Michael Lewis, Joe Gebbia, Michael Pollan, Dr. Jordan Peterson, Vince Vaughn, Brian Koppelman, Ramit Sethi, Dax Shepard, Tony Robbins, Jim Dethmer, Dan Harris, Ray Dalio, Naval Ravikant, Vitalik Buterin, Elizabeth Lesser, Amanda Palmer, Katie Haun, Sir Richard Branson, Chuck Palahniuk, Arianna Huffington, Reid Hoffman, Bill Burr, Whitney Cummings, Rick Rubin, Dr. Vivek Murthy, Darren Aronofsky, Margaret Atwood, Mark Zuckerberg, Peter Thiel, Dr. Gabor Maté, Anne Lamott, Sarah Silverman, Dr. Andrew Huberman, and many more.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
© 2020-2025 Ivy Podcast Discovery LLC
